| __timestamp | Amphastar Pharmaceuticals, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 8901000 |
| Thursday, January 1, 2015 | 174172000 | 9574000 |
| Friday, January 1, 2016 | 150976000 | 14695000 |
| Sunday, January 1, 2017 | 149380000 | 8437000 |
| Monday, January 1, 2018 | 187681000 | 12723000 |
| Tuesday, January 1, 2019 | 190434000 | 51272000 |
| Wednesday, January 1, 2020 | 206506000 | 50052000 |
| Friday, January 1, 2021 | 238029000 | 783000 |
| Saturday, January 1, 2022 | 250127000 | 868000 |
| Sunday, January 1, 2023 | 293274000 | 123740000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. Amphastar Pharmaceuticals, Inc. and Geron Corporation, two prominent players, showcase contrasting financial journeys from 2014 to 2023. Amphastar's cost of revenue has seen a steady climb, peaking at approximately $293 million in 2023, marking an impressive 84% increase from 2014. This growth reflects their expanding market presence and operational scale. In contrast, Geron Corporation's cost of revenue fluctuated significantly, with a notable spike in 2023, reaching around $124 million, a dramatic rise from previous years. This volatility may indicate strategic shifts or market challenges. The data highlights the diverse financial strategies within the pharmaceutical sector, offering insights into how companies navigate economic landscapes. As investors and analysts delve deeper, these trends provide a window into the operational efficiencies and market dynamics shaping the industry.
Cost Insights: Breaking Down Eli Lilly and Company and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Dr. Reddy's Laboratories Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Geron Corporation
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Geron Corporation
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Geron Corporation
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored